Chest

CHEST 2024: SGLT2 inhibitors linked to reduced mortality risk from PAH

October 10, 2024

SGLT2 inhibitors significantly reduced all-cause mortality in patients with pulmonary arterial hypertension (PAH). However, authors caution that further trials are necessary before changing clinical practice.

Using data from the TrinetX platform, investigators stratified patients diagnosed with PAH into two groups. In the SGLT2 inhibitor group (n = 6,238), patients were treated with one of the following medications: canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin, while patients in the control group (n = 6,243) were not. Results indicate a reduction in mortality for PAH patients using SGLT2 inhibitors:

• 1-year follow-up: 8.1% vs. 15.5%; absolute risk reduction [RR] 7.4% (RR 0.52, 95% CI, 0.473-0.58, p < 0.0001).
• 3-year follow-up: 13% vs. 22.5%; absolute RR 9.2% (RR 0.579, 95% CI, 0.535 - 0.627, p < 0.0001)
• 5-year follow-up: 14.6% vs. 25%; absolute RR 10.4% (RR 0.583, 95% CI, 0.542 - 0.628, p < 0.0001).

Source:

Lemonjava, I., et al. (2024, October). CHEST Journal. Impact of SGLT2 inhibitors on mortality in pulmonary arterial hypertension: Exploring the association. https://journal.chestnet.org/article/S0012-3692(24)04237-5/fulltext